Bio ReFine Ltd.

Bio-ReFine, an Israeli medical device company in the field of interventional structural cardiology, has developed a groundbreaking technology which enables physicians to perform implant-less annuloplasty repair in a simple and safe endovascular procedure. The Medical Need: • Millions of patients suffer from mitral or tricuspid valve regurgitation, a condition that causes blood to leak back into the heart atriums and reduces the heart's efficiency. • Current treatments for valve regurgitation are either invasive surgery or transcatheter interventions, which have significant limitations and risks, including: high mortality and morbidity rates (surgery), implant-related complications, need for lifelong anti-coagulation medication and anatomical restriction such as oversized valves (limiting transcatheter implants). • No viable transcatheter annuloplasty repair technology is currently available, creating a gap in the available heart valve repair "toolbox". Bio ReFine's technology offers a unique value proposition for patients and physicians, with the potential of reaching a significant share of the transcatheter valve repair market while supporting the valve replacement market.

• Employees 1